Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
LetterLetter

Understanding the Biological Significance of Anti-DFS70 Antibodies: Effect of Biologic Therapies on Their Occurrence in Inflammatory Arthritis

TERESA CARBONE, CARMELA ESPOSITO, VITO PAFUNDI, ANTONIO CARRIERO, MARIA CARMELA PADULA, ANGELA ANNA PADULA and SALVATORE D’ANGELO
The Journal of Rheumatology August 2020, 47 (8) 1295-1296; DOI: https://doi.org/10.3899/jrheum.191146
TERESA CARBONE
Rheumatology Institute of Lucania, and Immunopathology Laboratory, San Carlo Hospital, Potenza;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for TERESA CARBONE
CARMELA ESPOSITO
Rheumatology Division, Internal Medicine Department, Prato Hospital, Prato;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
VITO PAFUNDI
Immunopathology Laboratory, San Carlo Hospital, Potenza;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: vito.pafundi@ospedalesancarlo.it
ANTONIO CARRIERO
Rheumatology Institute of Lucania, San Carlo Hospital, Potenza;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for ANTONIO CARRIERO
MARIA CARMELA PADULA
Rheumatology Institute of Lucania, San Carlo Hospital, Potenza;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANGELA ANNA PADULA
Rheumatology Institute of Lucania, San Carlo Hospital, Potenza;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SALVATORE D’ANGELO
Rheumatology Institute of Lucania, San Carlo Hospital, Potenza, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

The anti-dense fine speckled 70 (anti-DFS70) antibodies have recently become of interest because of their occurring in heterogeneous disorders including chronic inflammatory conditions, cancer, and systemic autoimmune rheumatic diseases (SARD), as well as in healthy individuals1,2,3. The frequency of anti-DFS70 antibodies in rheumatoid arthritis (RA) ranged from 0 to 2.6%4. There have been no studies examining the frequency of anti-DFS70 antibodies in spondyloarthritis (SpA) as a group, while only 1 study evaluated anti-DFS70 positivity in ankylosing spondylitis (AS)5. These autoantibodies could play protective or pathogenic roles, but the factors inducing their trigger are still uncertain6. In particular, the effect of biological treatments, extensively used in SARD management, on anti-DFS70 antibodies expression has not yet been investigated and thus represents an intriguing matter. Despite a vast amount of data supporting a role of anti–tumor necrosis factor-α (TNF-α) agents in the occurrence of immunogenicity7, no data were available about these drugs’ effect on the occurrence of anti-DFS70 antibodies. In addition, the induction of autoimmune phenomena such as the drug-induced lupus erythematosus (DIL) syndrome was reported7. To our knowledge, no data regarding the relationship of these adverse reactions and the development of anti-DFS70 antibodies have been published. The aims of our study were first, to investigate the prevalence of anti-DFS70 antibodies in a large cohort of RA and SpA patients, and then to evaluate the effects of anti–TNF-α therapies on their development.

The study was conducted according to the principles of the Declaration of Helsinki and was approved by the Ethics Committee of Basilicata before the start of the study (705/2017). Informed consent was obtained from all patients included in the study.

We collected serum specimens from 100 adult patients with RA8 (87 female:13 male; mean age 55.4 ± 11.7 yrs; mean disease duration 14.4 ± 9.9 yrs), and 105 patients with SpA9 (50 female:55 male; mean age 54.0 ± 15.0 yrs; mean disease duration 18.2 ± 18.7 yrs) who attended the Rheumatology Institute of Lucania, Italy. Demographic and clinical data were obtained from medical records. Sera were tested for antinuclear antibodies (ANA) by indirect immunofluorescent (IIF; HEp-2000 Fluorescent ANA-RoTest System, Immuno Concepts), for anti-DFS70 antibodies by immunoblotting (IB; Alphadia, Wavre) and for anti–extractable nuclear antigen (ENA) autoantibodies by chemiluminescence (LIAISON XL, Diasorin).

We observed the nuclear DFS-IIF pattern in 11/100 RA and in 10/105 SpA serum samples, respectively. Four of 100 RA (4.0%) and 4/105 SpA patients (3.8%) were also positive against DFS70 by IB. All anti-DFS70–positive RA samples showed anti-ENA negativity while 1/4 SpA samples was also positive for anticentromere specificity. The frequencies of anti-DFS70 antibodies in both disease groups revealed no statistical differences (p > 0.05). In both groups, no significant differences were found between patients with and without anti-DFS70 antibodies in female:male ratio, disease duration, and mean age (p > 0.05). We also investigated the possible associations of anti-DFS70 antibody presence with clinical features or certain manifestations in both cohorts (Table 1). Interestingly, in the SpA group, all anti-DFS70–positive patients had a psoriatic arthritis (PsA) diagnosis. For each disease, we evaluated the effects of biologic agents on the occurrence of anti-DFS70 antibodies and ANA. In RA, 13 patients were ANA-positive at baseline and 1 was anti-DFS70–positive. ANA became positive after anti-TNF-α therapy in 36% (18/50) of the treated patients (p < 0.05; OR 0.27, 95% CI 0.12–0.60); 16.7% (3/18) of them showed anti-DFS70 pattern. In SpA, 8 patients were ANA-positive at baseline, while ANA became positive after anti-TNF-α therapy in 35.8% (24/67) of patients (p < 0.05; OR 0.15, 95% CI 0.06–0.36); 12.5% (3/24) of them were anti-DFS70 positive (Table 2). Notably, 1 SpA patient, ANA-negative at the first evaluation and treated with conventional disease-modifying antirheumatic drugs, developed the anti-DFS70 antibodies during the followup after a diagnosis of prostate cancer. No anti-DFS70–positive patients developed DIL while under treatment with anti–TNF-α therapy.

View this table:
  • View inline
  • View popup
Table 1.

Serological and clinical data of anti-DFS70–positive patients.

View this table:
  • View inline
  • View popup
Table 2.

Effect of anti–TNF-α treatment on ANA and anti-DFS70 antibody occurrence in patients with SpA and patients with RA.

To our knowledge, this is the first study investigating the prevalence of anti-DFS70 antibodies in a large cohort of patients with RA or SpA together with the effect of TNF-α blockers on their occurrence. In our RA cohort, we found a higher prevalence of anti-DFS70 antibodies positivity than the overall frequencies previously published5,10. Our findings in the SpA group showed a comparable prevalence. All anti-DFS70–positive SpA patients had a PsA diagnosis, thus all AS patients were anti-DFS70–negative according to previous evidence5. Interestingly, unlike findings in other SARD, the majority of anti-DFS70 antibodies in RA and SpA showed isolated reactivity. Our results on ANA induction by the TNF-α blockers are in agreement with those obtained in previous studies7. The strength of our study is the evaluation of the anti-DFS70 antibodies induction rate occurring after anti–TNF-α therapy, resulting in 6.0% and 4.5% of ANA-negative treated RA and SpA patients, respectively. Noteworthy in our cohorts, the majority of anti-DFS70 antibodies were negative before initiating biologics and were induced by anti–TNF-α agents. The exception of 1 SpA patient with prostate cancer history is supported by previous studies showing that the anti-DFS70 antibodies were significantly predominant in sera from prostate cancer patients compared to matched controls1.

The most significant result is that anti-DFS70 antibodies do not have a pathogenetic role, as supported by all the study findings. Owing to the low number of anti-DFS70–positive patients, further multicenter studies are required to validate these preliminary data.

REFERENCES

  1. 1.↵
    1. Ochs RL,
    2. Mahler M,
    3. Basu A,
    4. Rios-Colon L,
    5. Sanchez TW,
    6. Andrade LE,
    7. et al.
    The significance of autoantibodies to DFS70/LEDGFp75 in health and disease: integrating basic science with clinical understanding. Clin Exp Med 2016;16:273–93.
    OpenUrlCrossRef
  2. 2.↵
    1. Basu A,
    2. Rojas H,
    3. Banerjee H,
    4. Cabrera IB,
    5. Perez KY,
    6. De León M,
    7. et al.
    Expression of the stress response oncoprotein LEDGF/p75 in human cancer: a study of 21 tumor types. PLoS One 2012;7:e30132.
    OpenUrlPubMed
  3. 3.↵
    1. Mahler M,
    2. Hanly JG,
    3. Fritzler MJ
    . Importance of the dense fine speckled pattern on HEp-2 cells and anti-DFS70 antibodies for the diagnosis of systemic autoimmune diseases. Autoimmun Rev 2012;11:642–5.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Shovman O,
    2. Gilburd B,
    3. Chayat C,
    4. Amital H,
    5. Langevitz P,
    6. Watad A,
    7. et al.
    Prevalence of anti-DFS70 antibodies in patients with and without systemic autoimmune rheumatic diseases. Clin Exp Rheumatol 2018;36:121–6.
    OpenUrl
  5. 5.↵
    1. Peker BO,
    2. Şener AG,
    3. Tarhan EF,
    4. Kaya S
    . Investigation of anti-DFS70 antibody in patients with systemic autoimmune rheumatic diseases. Clin Rheumatol 2019;38: 3627–33.
    OpenUrl
  6. 6.↵
    1. Infantino M,
    2. Carbone T,
    3. Manfredi M,
    4. Grossi V,
    5. Benucci M,
    6. Blank M,
    7. et al.
    Are anti-DFS70 autoantibodies protective? Isr Med Assoc J 2019;21:509–11.
    OpenUrl
  7. 7.↵
    1. De Rycke L,
    2. Kruithof E,
    3. Van Damme N,
    4. Hoffman IE,
    5. Van den Bossche N,
    6. Van den Bosch F,
    7. et al.
    Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003;48:1015–23.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Aletaha D,
    2. Neogi T,
    3. Silman AJ,
    4. Funovits J,
    5. Felson DT,
    6. Bingham CO 3rd,
    7. et al.
    2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580–8.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Rudwaleit M,
    2. van der Heijde D,
    3. Landewé R,
    4. Akkoc N,
    5. Brandt J,
    6. Chou CT,
    7. et al.
    The Assessment of Spondyloarthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011;70:25–31.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Conrad K,
    2. Röber N,
    3. Andrade LE,
    4. Mahler M
    . The clinical relevance of anti-DFS70 autoantibodies. Clin Rev Allergy Immunol 2017;52:202–16.
    OpenUrlCrossRef
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 47, Issue 8
1 Aug 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Understanding the Biological Significance of Anti-DFS70 Antibodies: Effect of Biologic Therapies on Their Occurrence in Inflammatory Arthritis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Understanding the Biological Significance of Anti-DFS70 Antibodies: Effect of Biologic Therapies on Their Occurrence in Inflammatory Arthritis
TERESA CARBONE, CARMELA ESPOSITO, VITO PAFUNDI, ANTONIO CARRIERO, MARIA CARMELA PADULA, ANGELA ANNA PADULA, SALVATORE D’ANGELO
The Journal of Rheumatology Aug 2020, 47 (8) 1295-1296; DOI: 10.3899/jrheum.191146

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Understanding the Biological Significance of Anti-DFS70 Antibodies: Effect of Biologic Therapies on Their Occurrence in Inflammatory Arthritis
TERESA CARBONE, CARMELA ESPOSITO, VITO PAFUNDI, ANTONIO CARRIERO, MARIA CARMELA PADULA, ANGELA ANNA PADULA, SALVATORE D’ANGELO
The Journal of Rheumatology Aug 2020, 47 (8) 1295-1296; DOI: 10.3899/jrheum.191146
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
    • REFERENCES
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Rapidly Progressive Systemic Sclerosis–associated Interstitial Lung Disease After Intravesical Bacillus Calmette-Guérin Therapy for Early-stage Bladder Cancer
  • Axial Involvement in Psoriatic Arthritis: Effect on Peripheral Arthritis and Differential Features With Axial Spondyloarthritis in South America
  • The Effect of HLA-B27 on Susceptibility and Severity of COVID-19
Show more Letter

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire